Molecular characterization of multidrug-resistant Mycobacterium tuberculosis isolated in Nepal

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 6, 2012, Pages 2831-2836

  Poudel, Ajay ^a   Nakajima, Chie ^a   Fukushima, Yukari ^a   Suzuki, Haruka ^a   Pandey, Basu Dev ^b   Maharjan, Bhagwan ^c   Suzuki, Yasuhiko ^a,d  

^a HOKKAIDO UNIVERSITY   (Japan)

^b Sukraraj Tropical and Infectious Disease Hospital Kathmandu   (Nepal)

^c German Nepal Tuberculosis Project (GENETUP)   (Nepal)

^d JAPAN INTERNATIONAL COOPERATION AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; RIFAMPICIN; SERINE; STREPTOMYCIN; THREONINE;

AMINO ACID SUBSTITUTION; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; CODON; GENE MUTATION; INHA GENE; KATG GENE; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NEPAL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; RPOB GENE; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; DNA, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ISONIAZID; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; NEPAL; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84861142628     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06418-11     Document Type: Article

References (36)

1. Bakonyte D, Baranauskaite A, Cicenaite J, Anaida Sosnovskaja A, Stakenas P. 2003. Molecular characterization of isoniazid-resistant Mycobacterium tuberculosis clinical isolates in Lithuania. Antimicrob. Agents Chemother. 47:2009 -2011.
2. Canetti G, et al. 1969. Advances in techniques oftesting mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull. World Health Organ. 41:21- 43.
3. Caws M, et al. 2006. Mutations prevalent among rifampin- and isoniazid-resistant Mycobacterium tuberculosis isolates from a hospital in Vietnam. J. Clin. Microbiol. 44:2333-2337. (Pubitemid 44092394)
4. Guo JH, et al. 2008. Molecular characterization of drug-resistant Mycobacterium tuberculosis isolates from Sichuan Province in China. Jpn. J. Infect. Dis. 61:264 -268.
5. Hall A. 1999. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symp. Ser. (Oxford) 41:95-98.
6. Hazbon MH, et al. 2006. Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 50:2640 -2649.
7. Heep M, et al. 2001. Frequency of rpoB mutations inside and outside the cluster I region in rifampin-resistant clinical Mycobacterium tuberculosis isolates. J. Clin. Microbiol. 39:107-110. (Pubitemid 32059577)
8. Hillemann D, Weizenegger M, Kubica T, Richter E, Niemann S. 2005. Use of the genotype MTBDR assay for rapid detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis complex isolates. J. Clin. Microbiol. 43:699 -703.
9. Hirano K, Abe C, Takahashi M. 1999. Mutations in the rpoB gene of rifampin-resistant Mycobacterium tuberculosis strains isolated mostly in Asian countries and their rapid detection by line probe assay. J. Clin. Microbiol. 37:2663-2666. (Pubitemid 29337295)
10. Hu Y, Hoffner S, Jiang W, Wang W, Xu B. 2010. Extensive transmission of isoniazid resistant Mycobacterium tuberculosis and its association with increased multidrug-resistant TB in two rural counties of eastern China: a molecular epidemiological study. BMC Infect. Dis. 10:43.
11. Kiepiela P, Bishop KS, Smith AN, Roux L, York DF. 2000. Genomic mutations in the katG, inhA, and ahpC genes are useful for the prediction of isoniazid resistance in Mycobacterium tuberculosis isolates from Kwazulu Natal, South Africa. Tuberc. Lung Dis. 80:47-56. (Pubitemid 30179493)
12. Luo T, et al. 2010. Selection of mutations to detect multidrug resistant Mycobacterium tuberculosis strains in Shanghai, China. Antimicrob. Agents Chemother. 54:1075-1081.
13. Mahmoudi A, Iseman MD. 1993. Pitfalls in the care of patients with tuberculosis: common errors and their association with the acquisition of drug resistance. JAMA 270:65- 68.
14. Malla P, et al. 2009. Ambulatory-based standardized therapy for multidrug-resistant tuberculosis: experience from Nepal, 2005-2006. PLoS One 4:e8313.
15. Mani C, Selvakumar N, Narayanan S, Narayanan PR. 2001. Mutations in the rpoB gene of multidrug-resistant Mycobacterium tuberculosis clinical isolates from India. J. Clin. Microbiol. 39:2987-2990. (Pubitemid 32744028)
16. Mathuria JP, Nath G, Samaria JK, Anupurba S. 2009. Molecular characterization of INH-resistant Mycobacterium tuberculosis isolates by PCRRFLP and multiplex-PCR in North India. Infect. Genet. Evol. 9:1352-1355.
17. Mokrousov I, et al. 2002. High prevalence of KatGSer315Thr substitution among isoniazid-resistant Mycobacterium tuberculosis clinical isolates from northwestern Russia, 1996 to 2001. Antimicrob. Agents Chemother. 46:1417-1424. (Pubitemid 34415323)
18. Nakajima C, et al. 2010. Identification of Mycobacterium tuberculosis clinical isolates in Bangladesh by a species distinguishable multiplex PCR. BMC Infect. Dis. 10:118.
19. Nathanson E, et al. 2010. MDR tuberculosis-critical steps for prevention and control. N. Engl. J. Med. 363:1050-1058.
20. Nepal B. 2007. Population mobility and spread of HIV across the Indo-Nepal border. J. Health Popul. Nutr. 25:267-277. (Pubitemid 350244400)
21. Nettleman MD. 2005. Multidrug-resistant tuberculosis: news from the front. JAMA 293:2788-2790. (Pubitemid 40965091)
22. Nusrath UA, Selvakumar N, Narayanan S, Narayanan PR. 2008. Molecular analysis of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis from India. Int. J. Antimicrob. Agents 31:71-75. (Pubitemid 350236726)
23. Piatek AS, et al. 2000. Genotypic analysis of Mycobacterium tuberculosis in two distinct populations using molecular beacons: implications for rapid susceptibility testing. Antimicrob. Agents Chemother. 44:103-110. (Pubitemid 30010679)
24. Ramaswamy S, Musser JM. 1998. 1998. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: update. Tuberc. Lung Dis. 79:3-29. (Pubitemid 29050434)
25. Rouse DA, DeVito JA, Li Z, Byer H, Morris SL. 1996. Site-directed mutagenesis of the katG gene of Mycobacterium tuberculosis: effects on catalase-peroxidase activities and isoniazid resistance. Mol. Microbiol. 22: 583-592. (Pubitemid 26373841)
26. Sajduda A, et al. 2004. Molecular characterization of rifampin- and isoniazid-resistant Mycobacterium tuberculosis strains isolated in Poland. J. Clin. Microbiol. 42:2425-2431. (Pubitemid 38747484)
27. Siddiqi N, et al. 2002. Molecular characterization of multidrug-resistant isolates of Mycobacterium tuberculosis from patients in North India. Antimicrob. Agents Chemother. 46:443-450. (Pubitemid 34087194)
28. Suresh N, et al. 2006. rpoB gene sequencing and spoligotyping of multidrug- resistant Mycobacterium tuberculosis isolates from India. Infect. Genet. Evol. 6:474-483.
29. Suzuki Y, et al. 1998. Detection of kanamycin-resistant Mycobacterium tuberculosis by identifying mutations in the 16S rRNA gene. J. Clin. Microbiol. 36:1220-1225.
30. Telenti A, et al. 1993. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 341:647-650. (Pubitemid 23083244)
31. Valvatne H, et al. 2009. Isoniazid and rifampicin resistance-associated mutations in Mycobacterium tuberculosis isolates from Yangon, Myanmar: implications for rapid molecular testing. Antimicrob. Agents Chemother. 64:694 -701.
32. van Soolingen D, et al. 2000. Mutations at amino acid position 315 of the katG gene are associated with high-level resistance to isoniazid, other drug resistance, and successful transmission of Mycobacterium tuberculosis in the Netherlands. J. Infect. Dis. 182:1788-1790.
33. World Health Organization. 2001. Cross-border initiatives on HIV/AIDS, TB, malaria, and kala-azar: report of an intercountry meeting in Kathmandu, 6 to 9 March 2001. World Health Organization, Regional Office for South-East Asia, Geneva, Switzerland. http://whqlibdoc.who.int/searo/2001/SEA-CD-123.pdf.
34. World Health Organization. 2008. Molecular line probe assays for rapid screening of patients at risk of multidrug resistant tuberculosis (MDRTB). Policy statement, 2008. World Health Organization, Geneva, Switzerland. http://www.who.int/tb/dots/laboratory/line-probe-assays/en/index.html.
35. World Health Organization. 2010. Multidrug and extensively drugresistant TB (M/XDRTB): 2010 global report on surveillance and response. World Health Organization, Geneva, Switzerland. http://whqlibdoc.who.int/publications/2010/ 9789241599191-eng.
36. Yue J, et al. 2003. Mutations in the rpoB gene of multidrug-resistant Mycobacterium tuberculosis isolates from China. J. Clin. Microbiol. 41: 2209-2212. (Pubitemid 36576568)